Xintela to collaborate with Japanese CellSeed Inc.

Read as PDF

Lund, Sweden, 19th of December 2017 - Xintela AB (publ) announces today that the company has signed a collaboration agreement with the leading Japanese cell therapy company, CellSeed, for its development of a cell therapy product for the treatment of cartilage damage in the knee joint.

“It is very exciting that we have established a collaboration in Japan which, due to a new regulatory framework, has developed into a world-leading market in regenerative medicine”, says Xintela’s CEO Evy Lundgren-Åkerlund.

In the initial part of the collaboration, Xintela’s integrin marker technology and quality control assay XACT (Xintela Assay for Cell Therapy) will be evaluated for the quality control of cartilage cells used in CellSeed's product development. The collaboration aims to conduct experimental analyzes to evaluate Xintela's marker technology for use in a long-term collaboration and license.

“The fact that CellSeed chooses to evaluate XACT for quality control of its cartilage cell product, confirms the value of Xintela's marker technology and demonstrates the potential of XACT”, says Evy Lundgren-Åkerlund.

“Xintela has a unique and interesting integrin marker technology to control the quality of cartilage cells and we are very much looking forward to evaluating the markers for use in our product development”, says CellSeed’s CEO Setsuko Hashimoto.

About CellSeed Inc.
CellSeed Inc. is a leading Japanese company in regenerative medicine and is the first to employ the cutting-edge technology of ‘Cell sheet engineering’ as its technological platform to bring about fundamental changes in conventional medical treatments. CellSeed has started clinical trials with their ‘Esophageal Epithelial Cell Sheets’ for esophageal regeneration after cancer therapy, aiming to obtain market approval in 2019. The company has recently begun clinical trial preparations for the treatment of knee cartilage defects using Cell Sheets consisting of allogeneic chondrocytes. CellSeed Inc. is headquartered in Tokyo, Japan, and listed on the Tokyo stock exchange JASDAQ. Management: Setsuko Hashimoto (CEO), Jun Onodera (CFO).

For more information, visit: www.cellseed.com

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: 070-329 18 71
Email: evy@xintela.se
Medicon Village
223 81 Lund
www.xintela.se

For investor relations and media questions, please contact:
Mårten Svanberg, Laika Consulting
Tel: 070-362 70 05
Email: marten.svanberg@laika.se
www.laika.se

About Xintela
Xintela develops medical products for regenerative medicine and cancer based on its proprietary marker technology, XINMARK®. Xintela uses the technology to select and assure the quality of mesenchymal stem cells for the treatment of cartilage damage and osteoarthritis. In a study on horses, the company has shown that stem cells are safe to use and that they have a positive effect on the articular cartilage and the underlying bone after an injury. In addition, Xintela has developed an assay XACTTM for the quality control chondrocyte preprations in cell therapy of cartilage.    XINMARK® is also used for the development of an antibody-based treatment (Antibody Drug Conjugate, ADC) against glioblastoma, the most common and aggressive form of brain tumors in adults. Positive preclinical results from cell studies and animal model have shown that the antibody has a killing effect on glioblastoma cells and thus has confirmed the concept. Xintela is listed on Nasdaq First North Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00.

This information is such information that Xintela AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the above contact, for publication on the 19th of December 2017, at 08.50 CET.